Cargando…
Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review
Pembrolizumab is widely used in first-line treatment in patients with advanced non-small-cell lung cancer (NSCLC) with high PD-L1 expression. The activity of pembrolizumab in NSCLC patients with rare molecular alterations is poorly characterised. RET gene rearrangements are identified in 1–2% of lun...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949444/ https://www.ncbi.nlm.nih.gov/pubmed/35329956 http://dx.doi.org/10.3390/jcm11061630 |
_version_ | 1784674897710022656 |
---|---|
author | Knetki-Wróblewska, Magdalena Wojas-Krawczyk, Kamila Kowalski, Dariusz M. Krzakowski, Maciej |
author_facet | Knetki-Wróblewska, Magdalena Wojas-Krawczyk, Kamila Kowalski, Dariusz M. Krzakowski, Maciej |
author_sort | Knetki-Wróblewska, Magdalena |
collection | PubMed |
description | Pembrolizumab is widely used in first-line treatment in patients with advanced non-small-cell lung cancer (NSCLC) with high PD-L1 expression. The activity of pembrolizumab in NSCLC patients with rare molecular alterations is poorly characterised. RET gene rearrangements are identified in 1–2% of lung cancer patients. Here, we present two cases of RET-rearranged NSCLC patients with high PD-L1 expression (>50%), treated with pembrolizumab within routine clinical practice. Pembrolizumab was ineffective in both cases—single-agent immunotherapy seems to be of limited value in this group of patients. Selective RET-inhibitors, if available, are the optimal treatment for patients with RET fusion nowadays. The best sequence of the therapy is still not defined. |
format | Online Article Text |
id | pubmed-8949444 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89494442022-03-26 Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review Knetki-Wróblewska, Magdalena Wojas-Krawczyk, Kamila Kowalski, Dariusz M. Krzakowski, Maciej J Clin Med Review Pembrolizumab is widely used in first-line treatment in patients with advanced non-small-cell lung cancer (NSCLC) with high PD-L1 expression. The activity of pembrolizumab in NSCLC patients with rare molecular alterations is poorly characterised. RET gene rearrangements are identified in 1–2% of lung cancer patients. Here, we present two cases of RET-rearranged NSCLC patients with high PD-L1 expression (>50%), treated with pembrolizumab within routine clinical practice. Pembrolizumab was ineffective in both cases—single-agent immunotherapy seems to be of limited value in this group of patients. Selective RET-inhibitors, if available, are the optimal treatment for patients with RET fusion nowadays. The best sequence of the therapy is still not defined. MDPI 2022-03-15 /pmc/articles/PMC8949444/ /pubmed/35329956 http://dx.doi.org/10.3390/jcm11061630 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Knetki-Wróblewska, Magdalena Wojas-Krawczyk, Kamila Kowalski, Dariusz M. Krzakowski, Maciej Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review |
title | Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review |
title_full | Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review |
title_fullStr | Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review |
title_full_unstemmed | Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review |
title_short | Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review |
title_sort | non-small-cell lung cancer patients with coexistence of high pd-l1 expression and ret fusion—which path should we follow? case reports and literature review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949444/ https://www.ncbi.nlm.nih.gov/pubmed/35329956 http://dx.doi.org/10.3390/jcm11061630 |
work_keys_str_mv | AT knetkiwroblewskamagdalena nonsmallcelllungcancerpatientswithcoexistenceofhighpdl1expressionandretfusionwhichpathshouldwefollowcasereportsandliteraturereview AT wojaskrawczykkamila nonsmallcelllungcancerpatientswithcoexistenceofhighpdl1expressionandretfusionwhichpathshouldwefollowcasereportsandliteraturereview AT kowalskidariuszm nonsmallcelllungcancerpatientswithcoexistenceofhighpdl1expressionandretfusionwhichpathshouldwefollowcasereportsandliteraturereview AT krzakowskimaciej nonsmallcelllungcancerpatientswithcoexistenceofhighpdl1expressionandretfusionwhichpathshouldwefollowcasereportsandliteraturereview |